Metabolic bone disease in patients receiving home parenteral nutrition: A canadian study and review

Journal of Parenteral and Enteral Nutrition

Volumn 30, Issue 6, 2006, Pages 492-496

  Raman, M ^a   Aghdassi, E ^a   Baun, M ^a   Yeung, M ^a   Fairholm, L ^a   Saqui, O ^a   Allard, J P ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; PAMIDRONIC ACID;

ARTICLE; BONE DENSITY; DRUG EFFECT; FEMALE; HUMAN; MALE; METABOLIC BONE DISEASE; MIDDLE AGED; PARENTERAL NUTRITION; PHYSIOLOGY; PREVALENCE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK FACTOR; TIME; TREATMENT OUTCOME;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; DIPHOSPHONATES; FEMALE; HUMANS; MALE; MIDDLE AGED; PARENTERAL NUTRITION, HOME; PREVALENCE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34247482683     PISSN: 01486071     EISSN: None     Source Type: Journal    
DOI: 10.1177/0148607106030006492     Document Type: Article

References (30)

1. Pironi L, Labate AM, Pertkiewicz M, et al; Espen-Home Artificial Nutrition Working Group. Prevalence of bone disease in patients on home parenteral nutrition. Clin Nutr. 2002;21:289-296.
2. Shike M, Harrison JE, Sturtridge WC, et al. Metabolic bone disease in patients receiving long-term total parenteral nutrition. Ann Intern Med. 1980;92:343-350.
3. Harrison JE, Jeejeebhoy KN, Track NS. The effect of total parenteral nutrition (TPN) on bone mass. In: Coburn JW, Klein GL, eds. Metabolic Bone Disease in Total Parenteral Nutrition. Baltimore, MD: Urban and Schwarzenberg; 1985:53.
4. The TS, Kollee LA, Boon JM, Monnens LA. Rickets in a preterm infant during intravenous alimentation. Acta Paediatr Scand. 1983;72:769-771.
5. Cohen-Solal M, Baudoin C, Joly F, et al. Osteoporosis in patients on long-term home parenteral nutrition: a longitudinal study. J Bone Miner Res. 2003;18:1989-1994.
6. Espallargues M, Sampietro-Colom L, Estrada MD, et al. Identifying bone-mass-related risk factors for fracture to guide bone densitometry measurements: a systematic review of the literature. Osteoporos Int. 2001;12:811-822.
7. Bengoa JM, Sitrin MD, Wood RJ, Rosenberg IH. Amino acid-induced hypercalciuria in patients on total parenteral nutrition. Am J Clin Nutr. 1983;38:264-269.
8. Lau K, Goldfarb S, Goldberg M, Agus ZS. Effects of phosphate administration on tubular calcium transport. J Lab Clin Med. 1982;99:317-324.
9. Cunningham J, Fraher LJ, Clemens TL, Revell PA, Papapoulos SE. Chronic acidosis with metabolic bone disease: effect of alkali on bone morphology and vitamin D metabolism. Am J Med. 1998;73:199-204.
10. Ott SM, Maloney NA, Klein GL, et al. Aluminum is associated with low bone formation in patients receiving chronic parenteral nutrition. Ann Intern Med. 1983;98:910-914.
11. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254-1259.
12. Miller PD, Siris ES, Barrett-Connor E, et al. Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment. J Bone Miner Res. 2002;17:2222-2230.
13. European Prospective Osteoporosis Study (EPOS) Group. The relationship between bone density and incident vertebral fracture in men and women. J Bone Miner Res. 2002;17:2214-2221.
14. Nishikawa RA, Siepler SE, Siepler JK, et al. Intravenous pam-idronate improves bone mineral density in home parenteral nutrition patients. Clin Nutr. 2003;22:S88.
15. Genant HK, Cooper C, Poor G, et al. Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int. 1999;10:259-264.
16. Saitta JC, Ott SM, Sherrard D, Walden CE, Lipkin EW. Metabolic bone disease in adults receiving long-term parenteral nutrition: longitudinal study with regional densitometry and bone biopsy. JPEN J Parenter Enteral Nutr. 1993;17:214-219.
17. Verhage AH, Cheong WK, Allard JP, Jeejeebhoy KN. Increase in lumbar spine bone mineral content in patients on long-term parenteral nutrition without vitamin D supplementation. JPEN J Parenter Enteral Nutr. 1995;19:431-436.
18. Pironi L, Tjellesen L, De Francesco A, et al; ESPEN-Home Artificial Nutrition Working Group. Bone mineral density in patients on home parenteral nutrition: a follow-up study. Clin Nutr. 2004;23:1288-1302.
19. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Effect of cyclical intravenous clodronate therapy on bone mineral density and markers of bone turnover in patients receiving home parenteral nutrition. Am J Clin Nutr. 2002;76:482-488.
20. Lukert BP, Raisz LG. Glucocorticoid induced osteoporosis: pathogenesis and management. Ann Intern Med. 1990;112:352-364.
21. Morrison NA, Shine J, Fragonas JC, Verkest V, McMenemy ML, Eisman JA. 1,25-Dihydroxyvitamin D-responsive element and glucocorticoid repression in the osteocalcin gene. Science. 1989; 246:1158-1161.
22. Verhoeven AC, Boers M. Limited bone loss due to corticosteroids: a systematic review of prospective studies in rheumatoid arthritis and other diseases. J Rheumatol. 1997;24:1495-1503.
23. Mirtallo J, Canada T, Johnson D, et al; Task Force for the Revision of Safe Practices for Parenteral Nutrition. Safe practices for parenteral nutrition. JPEN J Parenter Enteral Nutr. 2004;28:S39-S70.
24. Adachi K, Chole RA. Inhibition of osteoclast recruitment at a local site by l-hydroxyethylidene-l,l-bisphosphonate (HEBP). Ann Otol Rhinol Laryngol. 1990;99(9 pt 1):738-741.
25. Carano A, Teitelbaum SL, Konsek JD, Schlesinger PH, Blair HC. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest. 1990;85: 456-461.
26. Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995;10:1478-1487.
27. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab. 2000;85:231-236.
28. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 1997;100:1475-1480.
29. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527-534.
30. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-1117.